Therapeutic applications of TRAIL receptor agonists in cancer and beyond

Pharmacology and Therapeutics

Volumn 155, Issue , 2015, Pages 117-131

  Amarante Mendes, Gustavo P ^a,b   Griffith, Thomas S ^c,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Nacional de CiÊncias e Tecnologia   (Brazil)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cancer; Cell death; Immune therapy; TRAIL

Indexed keywords

CASPASE; CONATUMUMAB; CYTOKINE RECEPTOR AGONIST; DEATH RECEPTOR; DROZITUMAB; DULANERMIN; HISTONE DEACETYLASE INHIBITOR; LBY 135; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; TIGATUZUMAB; TRAIL RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNITY; BIOLOGICAL ACTIVITY; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL DEATH; CHILDHOOD CANCER; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; LYMPHOMA; METASTASIS; NECROPTOSIS; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; TREATMENT INDICATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84945195508     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.09.001     Document Type: Review

References (320)

1. H. Abdullah, B. Brankin, C. Brady, and S.L. Cosby Wild-type measles virus infection upregulates poliovirus receptor-related 4 and causes apoptosis in brain endothelial cells by induction of tumor necrosis factor-related apoptosis-inducing ligand J Neuropathol Exp Neurol 72 2013 681 696
2. B.B. Aggarwal, and W.J. Kohr Human tumor necrosis factor Methods Enzymol 116 1985 448 456
3. O. Aktas, A. Smorodchenko, S. Brocke, C. Infante-Duarte, U. Schulze Topphoff, J. Vogt, and et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL Neuron 46 2005 421 432
4. M.L. Albert, M. Jegathesan, and R.B. Darnell Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells Nat Immunol 2 2001 1010 1017
5. M.R. Alderson, T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, and et al. Fas ligand mediates activation-induced cell death in human T lymphocytes J Exp Med 181 1995 71 77
6. M. Al-Kuhlani, J. Rothchild, S. Pal, L.M. de la Maza, S. Ouburg, S.A. Morre, and et al. TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans PLoS One 9 2014 e93939
7. G.P. Amarante-Mendes, and D.R. Green The regulation of apoptotic cell death Braz J Med Biol Res 32 1999 1053 1061
8. J.I. Andrews, T.S. Griffith, and J.L. Meier Cytomegalovirus and the role of interferon in the expression of tumor necrosis factor-related apoptosis-inducing ligand in the placenta Am J Obstet Gynecol 197 608 2007 e601 e606
9. T. Arai, Y. Akiyama, S. Okabe, K. Saito, T. Iwai, and Y. Yuasa Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas Cancer Lett 133 1998 197 204
10. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, and et al. Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155 162
11. N.S. Azahri, B.A. Di Bartolo, L.M. Khachigian, and M.M. Kavurma Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration J Cell Biochem 113 2012 2597 2606
12. K. Azijli, S. Yuvaraj, M.P. Peppelenbosch, T. Wurdinger, H. Dekker, J. Joore, and et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells J Cell Sci 125 2012 4651 4661
13. V.P. Badovinac, K.A. Messingham, T.S. Griffith, and J.T. Harty TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cells J Immunol 177 2006 999 1006
14. L. Barblu, K. Machmach, C. Gras, J.F. Delfraissy, F. Boufassa, M. Leal, and et al. Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-alpha and differentiate into functional killer pDCs under HIV activation J Infect Dis 206 2012 790 801
15. B.C. Barnhart, E.C. Alappat, and M.E. Peter The CD95 type I/type II model Semin Immunol 15 2003 185 193
16. M. Baud'huin, L. Duplomb, S. Teletchea, F. Lamoureux, C. Ruiz-Velasco, M. Maillasson, and et al. Osteoprotegerin: multiple partners for multiple functions Cytokine Growth Factor Rev 24 2013 401 409
17. A.A. Beg, and D. Baltimore An essential role for NF-kappaB in preventing TNF-alpha-induced cell death Science 274 1996 782 784
18. R.A. Bem, A.P. Bos, R.M. Wosten-van Asperen, M. Bruijn, R. Lutter, M.R. Sprick, and et al. Potential role of soluble TRAIL in epithelial injury in children with severe RSV infection Am J Respir Cell Mol Biol 42 2010 697 705
19. C.A. Benedict, P.S. Norris, T.I. Prigozy, J.L. Bodmer, J.A. Mahr, C.T. Garnett, and et al. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2 J Biol Chem 276 2001 3270 3278
20. S.R. Bennett, F.R. Carbone, F. Karamalis, J.F. Miller, and W.R. Heath Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help J Exp Med 186 1997 65 70
21. D. Belada, J. Mayer, M.S. Czuczman, I.W. Flinn, B. Durbin-Johnson, and G.L. Bray Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL) J Clin Oncol 28 2010 (abstract 8104)
22. A. Bisgin, A.D. Yalcin, and R.M. Gorczynski Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients Diabetes Res Clin Pract 96 2012 e84 e86
23. F. Blackhall, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, and et al. A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 (abstract 7534)
24. K.M. Boatright, M. Renatus, F.L. Scott, S. Sperandio, H. Shin, I.M. Pedersen, and et al. A unified model for apical caspase activation Mol Cell 11 2003 529 541
25. E. Bonfoco, P.M. Stuart, T. Brunner, T. Lin, T.S. Griffith, Y. Gao, and et al. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells Immunity 9 1998 711 720
26. P. Bonvini, E. Zorzi, G. Basso, and A. Rosolen Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma Leukemia 21 2007 838 842
27. E.L. Brincks, P. Gurung, R.A. Langlois, E.A. Hemann, K.L. Legge, and T.S. Griffith The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL J Immunol 187 2011 4581 4588
28. E.L. Brincks, A. Katewa, T.A. Kucaba, T.S. Griffith, and K.L. Legge CD8 T cells utilize TRAIL to control influenza virus infection J Immunol 181 2008 4918 4925
29. S. Brost, A. Zimmermann, R. Koschny, J. Sykora, W. Stremmel, P. Schirmacher, and et al. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection Pathol Res Pract 210 2014 83 91
30. Z. Cai, S. Jitkaew, J. Zhao, H.C. Chiang, S. Choksi, J. Liu, and et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis Nat Cell Biol 16 2014 55 65
31. D.R. Camidge, R.S. Herbst, M.S. Gordon, S.G. Eckhardt, R. Kurzrock, B. Durbin, and et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies Clin Cancer Res 16 2010 1256 1263
32. S.P. Cartland, J.H. Erlich, and M.M. Kavurma TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- mice PLoS One 9 2014 e92952
33. E.A. Carswell, L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci U S A. 72 9 1975 3666 3670
34. N. Casares, M.O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, and et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 2005 1691 1701
35. M.A. Cassatella, V. Huber, F. Calzetti, D. Margotto, N. Tamassia, G. Peri, and et al. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators J Leukoc Biol 79 2006 123 132
36. A. Cerami, and B. Beutler The role of cachectin/TNF in endotoxic shock and cachexia Immunol Today 9 1988 28 31
37. J. Chan, L. Prado-Lourenco, L.M. Khachigian, M.R. Bennett, B.A. Di Bartolo, and M.M. Kavurma TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner Circ Res 106 2010 1061 1071
38. P.M. Chaudhary, M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway Immunity 7 1997 821 830
39. S.P. Chawla, J. Tabernero, H.L. Kindler, E.G. Chiorean, P. LoRusso, M. Hsu, and et al. Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors J Clin Oncol 28 2010 (abstract 3102)
40. P.L. Chen, and A. Easton Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation J Vasc Res 45 2008 111 122
41. P.L. Chen, and A.S. Easton Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis Biochem Biophys Res Commun 391 2010 936 941
42. W. Chen, M.E. Frank, W. Jin, and S.M. Wahl TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu Immunity 14 2001 715 725
43. X. Chen, W. Li, J. Ren, D. Huang, W.T. He, Y. Song, and et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death Cell Res 24 2014 105 121
44. Y.S. Cho, S. Challa, D. Moquin, R. Genga, T.D. Ray, M. Guildford, and et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation Cell 137 2009 1112 1123
45. L. Ciesielski, and B. Modzelewski Pathogenesis and treatment of multiorgan failure dysfunction syndrome in shock Rocz Akad Med Bialymst 40 1995 13 24
46. J.J. Cohen Apoptosis Immunol Today 14 1993 126 130
47. A.L. Cohn, J. Tabernero, J. Maurel, E. Nowara, J. Sastre, B.Y. Chuah, and et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer Ann Oncol 24 2013 1777 1785
48. N. Corazza, G. Brumatti, S. Jakob, A. Villunger, and T. Brunner TRAIL and thymocyte apoptosis: not so deadly? Cell Death Differ 11 Suppl. 2 2004 S213 S215
49. V.S. Cortez, A. Fuchs, M. Cella, S. Gilfillan, and M. Colonna Cutting edge: salivary gland NK cells develop independently of Nfil3 in steady-state J Immunol 192 2014 4487 4491
50. E. Cretney, J.L. McQualter, N. Kayagaki, H. Yagita, C.C. Bernard, I.S. Grewal, and et al. TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice Immunol Cell Biol 83 2005 511 519
51. E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J.J. Peschon, and M.J. Smyth Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J Immunol 168 2002 1356 1361
52. E. Cretney, A.P. Uldrich, F.W. McNab, D.I. Godfrey, and M.J. Smyth No requirement for TRAIL in intrathymic negative selection Int Immunol 20 2008 267 276
53. S.P. Cullen, C.M. Henry, C.J. Kearney, S.E. Logue, M. Feoktistova, G.A. Tynan, and et al. Fas/CD95-induced chemokines can serve as "find-me" signals for apoptotic cells Mol Cell 49 2013 1034 1048
54. X. Dai, J. Zhang, F. Arfuso, A. Chinnathambi, M.E. Zayed, S.A. Alharbi, and et al. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Exp Biol Med 240 6 2015 760 773
55. D.D. De Carvalho, R. Binato, W.O. Pereira, J.M. Leroy, M.D. Colassanti, R. Proto-Siqueira, and et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients Oncogene 30 2011 223 233
56. D.D. De Carvalho, B.P. Mello, W.O. Pereira, and G.P. Amarante-Mendes PRAME/EZH2-mediated regulation of TRAIL: a new target for cancer therapy Curr Mol Med 13 2013 296 304
57. M.A. Degli-Esposti, W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwin The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity 7 1997 813 820
58. M.A. Degli-Esposti, P.J. Smolak, H. Walczak, J. Waugh, C.-P. Huang, R.F. DuBose, and et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family J Exp Med 186 1997 1165 1170
59. D. Delmas, C. Rebe, O. Micheau, A. Athias, P. Gambert, S. Grazide, and et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells Oncogene 23 2004 8979 8986
60. G.D. Demetri, A. Le Cesne, S.P. Chawla, T. Brodowicz, R.G. Maki, B.A. Bach, and et al. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study Eur J Cancer 48 2012 547 563
61. Y. Deng, Y. Lin, and X. Wu TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO Genes Dev 16 2002 33 45
62. B.A. Di Bartolo, S.P. Cartland, H.H. Harith, Y.V. Bobryshev, M. Schoppet, and M.M. Kavurma TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL PLoS One 8 2013 e74211
63. B.A. Di Bartolo, J. Chan, M.R. Bennett, S. Cartland, S. Bao, B.E. Tuch, and et al. TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe (-)/(-) mice Diabetologia 54 2011 3157 3167
64. T. Doi, H. Murakami, A. Ohtsu, N. Fuse, T. Yoshino, N. Yamamoto, and et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 68 2011 733 741
65. Y. Dondelinger, W. Declercq, S. Montessuit, R. Roelandt, A. Goncalves, I. Bruggeman, and et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates Cell Rep 7 2014 971 981
66. G.P. Dunn, C.M. Koebel, and R.D. Schreiber Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 2006 836 848
67. B.D. Elzey, T.S. Griffith, J.M. Herndon, R. Barreiro, J. Tschopp, and T.A. Ferguson Regulation of Fas ligand-induced apoptosis by TNF J Immunol 167 2001 3049 3056
68. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, and et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 1998 14363 14367
69. V.A. Fadok, D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, and P.M. Henson Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF J Clin Invest 101 1998 890 898
70. N.A. Fanger, C.R. Maliszewski, K. Schooley, and T.S. Griffith Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) J Exp Med 190 1999 1155 1164
71. S. Feau, Z. Garcia, R. Arens, H. Yagita, J. Borst, and S.P. Schoenberger The CD4(+) T-cell help signal is transmitted from APC to CD8(+) T-cells via CD27-CD70 interactions Nat Commun 3 2012 948
72. + T cells produce active immune unresponsiveness J Immunol 168 2002 5589 5595
73. T.A. Ferguson, P.M. Stuart, J.M. Herndon, and T.S. Griffith Apoptosis, tolerance, and regulatory T cells - old wine, new wineskins Immunol Rev 193 2003 111 123
74. M. Ferrantini, I. Capone, and F. Belardelli Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use Biochimie 89 2007 884 893
75. D. Finlay, M. Vamos, M. Gonzalez-Lopez, R.J. Ardecky, S.R. Ganji, H. Yuan, and et al. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs Mol Cancer Ther 13 2014 5 15
76. A. Forero-Torres, J.R. Infante, D. Waterhouse, L. Wong, S. Vickers, E. Arrowsmith, and et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer Cancer Med 2 2013 925 932
77. A. Forero-Torres, J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, and et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) Cancer Biother Radiopharm 25 2010 13 19
78. A. Forero-Torres, K.E. Varley, V. Abramson, Y. Li, C. Vaklavas, N.U. Lin, and et al. TBCRC 019: phase II trial of nab-PAC with/without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer Clin Cancer Res Off J Am Assoc Cancer Res 2015
79. C.S. Fuchs, M. Fakih, L. Schwartzberg, A.L. Cohn, L. Yee, L. Dreisbach, and et al. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial Cancer 119 2013 4290 4298
80. M.B. Fuertes, A.K. Kacha, J. Kline, S.R. Woo, D.M. Kranz, K.M. Murphy, and et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha} + dendritic cells J Exp Med 208 2011 2005 2016
81. S. Fulda Modulation of TRAIL-induced apoptosis by HDAC inhibitors Curr Cancer Drug Targets 8 2008 132 140
82. S. Fulda Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis Exp Cell Res 318 2012 1208 1212
83. S. Fulda Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) Adv Exp Med Biol 818 2014 167 180
84. S. Fulda, and K.M. Debatin HDAC inhibitors: double edge sword for TRAIL cancer therapy? Cancer Biol Ther 4 2005 1113 1115
85. S. Fulda, E. Meyer, and K.M. Debatin Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression Oncogene 21 2002 2283 2294
86. L. Galluzzi, O. Kepp, S. Krautwald, G. Kroemer, and A. Linkermann Molecular mechanisms of regulated necrosis Semin Cell Dev Biol 35 2014 24 32
87. M. Gandini, C. Gras, E.L. Azeredo, L.M. Pinto, N. Smith, P. Despres, and et al. Dengue virus activates membrane TRAIL relocalization and IFN-alpha production by human plasmacytoid dendritic cells in vitro and in vivo PLoS Negl Trop Dis 7 2013 e2257
88. Y. Gao, J.M. Herndon, H. Zhang, T.S. Griffith, and T.A. Ferguson Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis J Exp Med 188 1998 887 896
89. S. Gillespie, J. Borrow, X.D. Zhang, and P. Hersey Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells Apoptosis 11 2006 2251 2265
90. G.A. Granger, and W.P. Kolb Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction J Immunol 101 1 1968 111 120
91. C. Gras, N. Smith, L. Sengmanivong, M. Gandini, C.F. Kubelka, and J.P. Herbeuval TRAIL protein localization in human primary T cells by 3D microscopy using 3D interactive surface plot: a new method to visualize plasma membrane J Immunol Methods 387 2013 147 156
92. J.D. Graves, J.J. Kordich, T.H. Huang, J. Piasecki, T.L. Bush, T. Sullivan, and et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity Cancer Cell 26 2014 177 189
93. F.A. Greco, P. Bonomi, J. Crawford, K. Kelly, Y. Oh, W. Halpern, and et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer Lung Cancer 61 2008 82 90
94. D.R. Green, T. Ferguson, L. Zitvogel, and G. Kroemer Immunogenic and tolerogenic cell death Nat Rev Immunol 9 2009 353 363
95. T.S. Griffith, E.L. Brincks, P. Gurung, T.A. Kucaba, and T.A. Ferguson Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells J Immunol 186 2011 791 798
96. T.S. Griffith, and E.L. Broghammer Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus Mol Ther 4 2001 257 266
97. T.S. Griffith, T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1995 1189 1192
98. T.S. Griffith, W.A. Chin, G.C. Jackson, D.H. Lynch, and M.Z. Kubin Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells J Immunol 161 1998 2833 2840
99. T.S. Griffith, and T.A. Ferguson Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells Immunity 35 2011 456 466
100. T.S. Griffith, J.M. Fialkov, D.L. Scott, T. Azuhata, R.D. Williams, N.R. Wall, and et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma Cancer Res 62 2002 3093 3099
101. + T cells that produce TRAIL J Immunol 178 2007 2679 2687
102. T.S. Griffith, and D.H. Lynch TRAIL: a molecule with multiple receptors and control mechanisms Curr Opin Immunol 10 1998 559 563
103. T.S. Griffith, S.R. Wiley, M.Z. Kubin, L.M. Sedger, C.R. Maliszewski, and N.A. Fanger Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL J Exp Med 189 1999 1343 1354
104. P. Gurung, T.A. Kucaba, S.P. Schoenberger, T.A. Ferguson, and T.S. Griffith TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion J Leukoc Biol 88 2010 1217 1225
105. P. Gurung, D. Rai, S.A. Condotta, J.C. Babcock, V.P. Badovinac, and T.S. Griffith Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent J Immunol 187 2011 2148 2154
106. S. Hacker, A. Dittrich, A. Mohr, T. Schweitzer, S. Rutkowski, J. Krauss, and et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8 Oncogene 28 2009 3097 3110
107. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, and et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape Science 274 1996 1363 1366
108. H. Hamada, E. Bassity, A. Flies, T.M. Strutt, L. Garcia-Hernandez Mde, K.K. McKinstry, and et al. Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection J Immunol 190 2013 296 306
109. A.G. Hameed, N.D. Arnold, J. Chamberlain, J.A. Pickworth, C. Paiva, S. Dawson, and et al. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension J Exp Med 209 2012 1919 1935
110. S.E. Hamilton, M.C. Wolkers, S.P. Schoenberger, and S.C. Jameson The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells Nat Immunol 7 2006 475 481
111. N.M. Haynes, E.D. Hawkins, M. Li, N.M. McLaughlin, G.J. Hammerling, R. Schwendener, and et al. CD11c + dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors J Immunol 185 2010 532 541
112. S. He, L. Wang, L. Miao, T. Wang, F. Du, L. Zhao, and et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha Cell 137 2009 1100 1111
113. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, M.S. Gordon, and et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J Clin Oncol 28 2010 2839 2846
114. R.S. Herbst, R. Kurzrock, D.S. Hong, M. Valdivieso, C.P. Hsu, L. Goyal, and et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors Clin Cancer Res Off J Am Assoc Cancer Res 16 2010 5883 5891
115. B. Hilliard, A. Wilmen, C. Seidel, T.S. Liu, R. Goke, and Y. Chen Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis J Immunol 166 2001 1314 1319
116. S. Hinz, A. Trauzold, L. Boenicke, C. Sandberg, S. Beckmann, E. Bayer, and et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis Oncogene 19 2000 5477 5486
117. L.C. Hofbauer, M. Schoppet, M. Christ, J. Teichmann, and U. Lange Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis Rheumatology (Oxford) 45 2006 1218 1222
118. O. Hoffmann, J. Priller, T. Prozorovski, U. Schulze-Topphoff, N. Baeva, J.D. Lunemann, and et al. TRAIL limits excessive host immune responses in bacterial meningitis J Clin Invest 117 2007 2004 2013
119. N. Holler, R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, and et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule Nat Immunol 1 2000 489 495
120. P. Horak, D. Pils, G. Haller, I. Pribill, M. Roessler, S. Tomek, and et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer Mol Cancer Res 3 2005 335 343
121. P. Horak, D. Pils, A. Kaider, A. Pinter, K. Elandt, C. Sax, and et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5 Clin Cancer Res 11 2005 8585 8591
122. S.J. Hotte, H.W. Hirte, E.X. Chen, L.L. Siu, L.H. Le, A. Corey, and et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies Clin Cancer Res 14 2008 3450 3455
123. K.E. Hubert, M.H. Davies, A.J. Stempel, T.S. Griffith, and M.R. Powers TRAIL-deficient mice exhibit delayed regression of retinal neovascularization Am J Pathol 175 2009 2697 2708
124. S. Inoue, M. MacFarlane, N. Harper, L.M. Wheat, M.J. Dyer, and G.M. Cohen Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies Cell Death Differ 11 Suppl. 2 2004 S193 S206
125. E. Ishikawa, M. Nakazawa, M. Yoshinari, and M. Minami Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice J Virol 79 2005 7658 7663
126. N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, and et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell 66 1991 233 243
127. + T-cell memory via TRAIL-mediated activation-induced cell death Nature 434 2005 88 93
128. R.W. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 2002 287 299
129. P.J. Jost, S. Grabow, D. Gray, M.D. McKenzie, U. Nachbur, D.C. Huang, and et al. XIAP discriminates between type I and type II FAS-induced apoptosis Nature 460 2009 1035 1039
130. Y.H. Jung, E.J. Lim, J. Heo, T.K. Kwon, and Y.H. Kim Tunicamycin sensitizes human prostate cells to TRAIL-induced apoptosis by upregulation of TRAIL receptors and downregulation of cIAP2 Int J Oncol 40 2012 1941 1948
131. A. Kaczmarek, P. Vandenabeele, and D.V. Krysko Necroptosis: the release of damage-associated molecular patterns and its physiological relevance Immunity 38 2013 209 223
132. H. Kamohara, W. Matsuyama, O. Shimozato, K. Abe, C. Galligan, S. Hashimoto, and et al. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils Immunology 111 2004 186 194
133. B. Karacay, S. Sanlioglu, T.S. Griffith, A. Sandler, and D.J. Bonthius Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells Cancer Gene Ther 11 2004 681 690
134. S.M. Kasubhai, J.C. Bendell, M. Kozloff, A.V. Kapp, A. Ashkenazi, S. Royer-Joo, and et al. Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 30 2012 (abstract 3543)
135. M.M. Kavurma, and M.R. Bennett Expression, regulation and function of trail in atherosclerosis Biochem Pharmacol 75 2008 1441 1450
136. M.M. Kavurma, M. Schoppet, Y.V. Bobryshev, L.M. Khachigian, and M.R. Bennett TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor J Biol Chem 283 2008 7754 7762
137. N. Kayagaki, N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and H. Yagita Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs J Exp Med 189 1999 1451 1460
138. H. Kazama, J.E. Ricci, J.M. Herndon, G. Hoppe, D.R. Green, and T.A. Ferguson Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein Immunity 29 2008 21 32
139. M.M. Keane, Y. Rubinstein, M. Cuello, S.A. Ettenberg, P. Banerjee, M.M. Nau, and et al. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines Breast Cancer Res Treat 64 2000 211 219
140. C.J. Kearney, S.P. Cullen, G.A. Tynan, C.M. Henry, D. Clancy, E.C. Lavelle, and et al. Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production Cell Death Differ 22 2015 1313 1327
141. C.J. Kearney, C. Sheridan, S.P. Cullen, G.A. Tynan, S.E. Logue, I.S. Afonina, and et al. Inhibitor of apoptosis proteins (IAPs) and their antagonists regulate spontaneous and tumor necrosis factor (TNF)-induced proinflammatory cytokine and chemokine production J Biol Chem 288 2013 4878 4890
142. T.J. Kemp, B.D. Elzey, and T.S. Griffith Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation J Immunol 171 2003 212 218
143. T.J. Kemp, J.-S. Kim, S.A. Crist, and T.S. Griffith Induction of necrotic tumor cell death by TRAIL/Apo-2L Apoptosis 8 2003 587 599
144. T.J. Kemp, A.T. Ludwig, J.K. Earel, J.M. Moore, R.L. Vanoosten, B. Moses, and et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 106 2005 3474 3482
145. T.J. Kemp, J.M. Moore, and T.S. Griffith Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation J Immunol 173 2004 892 899
146. K. Kimura, T. Taguchi, I. Urushizaki, R. Ohno, O. Abe, H. Furue, and et al. Phase I study of recombinant human tumor necrosis factor Cancer Chemother Pharmacol 20 1987 223 229
147. H.L. Kindler, D.A. Richards, L.E. Garbo, E.B. Garon, J.J. Stephenson Jr., C.M. Rocha-Lima, and et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer Ann Oncol 23 2012 2834 2842
148. W.P. Kolb, and G.A. Granger Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin Proc Natl Acad Sci U S A. 61 4 1968 1250 1255
149. S. Kuerten, R.J. Asaad, S.P. Schoenberger, D.N. Angelov, P.V. Lehmann, and M. Tary-Lehmann The TRAIL of helpless CD8+ T cells in HIV infection AIDS Res Hum Retrovir 24 2008 1175 1183
150. B.M. Kurbanov, L.F. Fecker, C.C. Geilen, W. Sterry, and J. Eberle Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4 Oncogene 26 2007 3364 3377
151. C. Kurts, W.R. Heath, F.R. Carbone, J. Allison, J.F. Miller, and H. Kosaka Constitutive class I-restricted exogenous presentation of self antigens in vivo J Exp Med 184 1996 923 930
152. S.E. Lamhamedi-Cherradi, S.J. Zheng, K.A. Maguschak, J. Peschon, and Y.H. Chen Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice Nat Immunol 4 2003 255 260
153. S.E. Lamhamedi-Cherradi, S. Zheng, R.M. Tisch, and Y.H. Chen Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes Diabetes 52 2003 2274 2278
154. H.O. Lee, J.M. Herndon, R. Barreiro, T.S. Griffith, and T.A. Ferguson TRAIL: a mechanism of tumor surveillance in an immune privileged site J Immunol 169 2002 4739 4744
155. S.H. Lee, M.S. Shin, H.S. Kim, H.K. Lee, W.S. Park, S.Y. Kim, and et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers Cancer Res 59 1999 5683 5686
156. S. Leong, R.B. Cohen, D.L. Gustafson, C.J. Langer, D.R. Camidge, K. Padavic, and et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study J Clin Oncol 27 2009 4413 4421
157. J.H. Li, N.C. Kirkiles-Smith, J.M. McNiff, and J.S. Pober TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells J Immunol 171 2003 1526 1533
158. J. Li, T. McQuade, A.B. Siemer, J. Napetschnig, K. Moriwaki, Y.S. Hsiao, and et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis Cell 150 2012 339 350
159. L. Li, R.M. Thomas, H. Suzuki, J.K. De Brabander, X. Wang, and P.G. Harran A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death Science 305 2004 1471 1474
160. D.L. Lichtenstein, K. Doronin, K. Toth, M. Kuppuswamy, W.S. Wold, and A.E. Tollefson Adenovirus E3-6.7 K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2 J Virol 78 2004 12297 12307
161. D. Limonta, A. Torrentes-Carvalho, C.F. Marinho, E.L. de Azeredo, L.J. de Souza, A.R. Motta-Castro, and et al. Apoptotic mediators in patients with severe and non-severe dengue from Brazil J Med Virol 86 2014 1437 1447
162. W.C. Lin, H.F. Tsai, H.J. Liao, C.H. Tang, Y.Y. Wu, P.I. Hsu, and et al. Helicobacter pylori sensitizes TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human gastric epithelial cells through regulation of FLIP Cell Death Dis 5 2014 e1109
163. A. Linkermann, and D.R. Green Necroptosis N Engl J Med 370 2014 455 465
164. Z. Liu, X. Xu, H.C. Hsu, A. Tousson, P.A. Yang, Q. Wu, and et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis J Clin Invest 112 2003 1332 1341
165. M.N. Lub-de Hooge, E.G. de Vries, S. de Jong, and M. Bijl Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus Ann Rheum Dis 64 2005 854 858
166. A.T. Ludwig, J.M. Moore, Y. Luo, X. Chen, N.A. Saltsgaver, M.A. O'Donnell, and et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity Cancer Res 64 2004 3386 3390
167. M. MacFarlane, M. Ahmad, S.M. Srinivasula, T. Fernandes-Alnemri, G.M. Cohen, and E.S. Alnemri Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL J Biol Chem 272 1997 25417 25420
168. S.A. Marsters, J.P. Sheridan, R.M. Pitti, A. Huang, M. Skubatch, D. Baldwin, and et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain Curr Biol 7 1997 1003 1006
169. R. Matsumura, K. Umemiya, M. Kagami, H. Tomioka, E. Tanabe, T. Sugiyama, and et al. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome Clin Exp Rheumatol 20 2002 791 798
170. F. McNab, K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra Type I interferons in infectious disease Nat Rev Immunol 15 2015 87 103
171. M.S. Merchant, J.I. Geller, K. Baird, A.J. Chou, S. Galli, A. Charles, and et al. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors J Clin Oncol 30 2012 4141 4147
172. M.S. Merchant, X. Yang, F. Melchionda, M. Romero, R. Klein, C.J. Thiele, and et al. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma Cancer Res 64 2004 8349 8356
173. Q.S. Mi, D. Ly, S.E. Lamhamedi-Cherradi, K.V. Salojin, L. Zhou, M. Grattan, and et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice Diabetes 52 2003 1967 1975
174. Y. Michowitz, E. Goldstein, A. Roth, A. Afek, A. Abashidze, Y. Ben Gal, and et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis J Am Coll Cardiol 45 2005 1018 1024
175. N. Mitsiades, C.S. Mitsiades, V. Poulaki, K.C. Anderson, and S.P. Treon Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells Blood 99 2002 2162 2171
176. J. Mitsui, H. Nishikawa, D. Muraoka, L. Wang, T. Noguchi, E. Sato, and et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals Clin Cancer Res 16 2010 2781 2791
177. C.H. Mom, J. Verweij, C.N. Oldenhuis, J.A. Gietema, N.L. Fox, R. Miceli, and et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study Clin Cancer Res 15 2009 5584 5590
178. J. Mongkolsapaya, A.E. Cowper, X.N. Xu, G. Morris, A.J. McMichael, J.I. Bell, and et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL J Immunol 160 1998 3 6
179. S. Mori, K. Murakami-Mori, S. Nakamura, A. Ashkenazi, and B. Bonavida Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D J Immunol 162 1999 5616 5623
180. J.M. Murphy, P.E. Czabotar, J.M. Hildebrand, I.S. Lucet, J.G. Zhang, S. Alvarez-Diaz, and et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism Immunity 39 2013 443 453
181. M. Muzio, B.R. Stockwell, H.R. Stennicke, G.S. Salvesen, and V.M. Dixit An induced proximity model for caspase-8 activation J Biol Chem 273 1998 2926 2930
182. T. Newsom-Davis, S. Prieske, and H. Walczak Is TRAIL the holy grail of cancer therapy? Apoptosis 14 2009 607 623
183. C.P. Ng, and B. Bonavida X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO) Mol Cancer Ther 1 2002 1051 1058
184. M. Obeid, A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh, J.L. Perfettini, and et al. Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 2007 54 61
185. J. Ogasawara, R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, and et al. Lethal effect of the anti-Fas antibody in mice Nature 364 1993 806 809
186. S. Orozco, N. Yatim, M.R. Werner, H. Tran, S.Y. Gunja, S.W. Tait, and et al. RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis Cell Death Differ 21 2014 1511 1521
187. W. Ouyang, C. Yang, S. Zhang, Y. Liu, B. Yang, J. Zhang, and et al. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells Int J Oncol 42 2013 699 711
188. N. Ozoren, M.J. Fisher, K. Kim, C.X. Liu, A. Genin, Y. Shifman, and et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance Int J Oncol 16 2000 917 925
189. S.I. Pai, G.S. Wu, N. Ozoren, L. Wu, J. Jen, D. Sidransky, and et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer Cancer Res 58 1998 3513 3518
190. G. Pan, J. Ni, Y.F. Wei, G. Yu, R. Gentz, and V.M. Dixit An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277 1997 815 818
191. G. Pan, J. Ni, G. Yu, Y.F. Wei, and V.M. Dixit TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling FEBS Lett 424 1998 41 45
192. G. Pan, K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and et al. The receptor for the cytotoxic ligand TRAIL Science 276 1997 111 113
193. L. Paz-Ares, B. Balint, R.H. de Boer, J.P. van Meerbeeck, R. Wierzbicki, P. De Souza, and et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first- line treatment of advanced non-small-cell lung cancer J Thorac Oncol 8 2013 329 337
194. D. Pennica, G.E. Nedwin, J.S. Hayflick, P.H. Seeburg, R. Derynck, M.A. Palladino, and et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin Nature 312 1984 724 729
195. R. Penta, M. De Falco, G. Iaquinto, and A. De Luca Helicobacter pylori and gastric epithelial cells: from gastritis to cancer J Exp Clin Cancer Res 24 2005 337 345
196. W.O. Pereira, and G.P. Amarante-Mendes Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73 2011 401 407
197. T.A. Phillips, J. Ni, G. Pan, S.M. Ruben, Y.F. Wei, J.L. Pace, and et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege J Immunol 162 1999 6053 6059
198. R.M. Pitti, S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, and A. Ashkenazi Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem 271 1996 12687 12690
199. R. Plummer, G. Attard, S. Pacey, L. Li, A. Razak, R. Perrett, and et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers Clin Cancer Res 13 2007 6187 6194
200. L.B. Pritzker, M. Scatena, and C.M. Giachelli The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival Mol Biol Cell 15 2004 2834 2841
201. H. Qiu, Y. Fan, A.G. Joyee, S. Wang, X. Han, H. Bai, and et al. Type I IFNs enhance susceptibility to Chlamydia muridarum lung infection by enhancing apoptosis of local macrophages J Immunol 181 2008 2092 2102
202. N.V. Rajeshkumar, Z.A. Rasheed, E. Garcia-Garcia, F. Lopez-Rios, K. Fujiwara, W.H. Matsui, and et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model Mol Cancer Ther 9 2010 2582 2592
203. R. Ravi, G.C. Bedi, L.W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, and et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB Nat Cell Biol 3 2001 409 416
204. M. Reck, M. Krzakowski, E. Chmielowska, M. Sebastian, D. Hadler, T. Fox, and et al. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer Lung Cancer 82 2013 441 448
205. J.S. Riley, R. Hutchinson, D.G. McArt, N. Crawford, C. Holohan, I. Paul, and et al. Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer Cell Death Dis 4 2013 e951
206. C.M. Rocha Lima, S. Bayraktar, A.M. Flores, J. MacIntyre, A. Montero, J.C. Baranda, and et al. Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer Cancer Invest 30 2012 727 731
207. R.R. Rosato, J.A. Almenara, Y. Dai, and S. Grant Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells Mol Cancer Ther 2 2003 1273 1284
208. A. Rossin, M. Derouet, F. Abdel-Sater, and A.O. Hueber Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling Biochem J 419 2009 185 192 (182 p following 192)
209. J.A. Sacks, and M.J. Bevan TRAIL deficiency does not rescue impaired CD8+ T cell memory generated in the absence of CD4+ T cell help J Immunol 180 2008 4570 4576
210. L. Saltz, J. Infante, L. Schwartzberg, J. Stephens, C. Rocha-Lima, F. Galimi, and et al. Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 27 2009 (abstract 4079)
211. A. Samali, and S. Orrenius Heat shock proteins: regulators of stress response and apoptosis Cell Stress Chaperones 3 1998 228 236
212. K. Sato, T. Nuki, K. Gomita, C.M. Weyand, and N. Hagiwara Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome Atherosclerosis 213 2010 33 39
213. P. Schneider, J.L. Bodmer, M. Thome, K. Hofmann, N. Holler, and J. Tschopp Characterization of two receptors for TRAIL FEBS Lett 416 1997 329 334
214. P. Schneider, M. Thome, K. Burns, J.L. Bodmer, K. Hofmann, T. Kataoka, and et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB Immunity 7 1997 831 836
215. S.P. Schoenberger, R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 1998 480 483
216. M. Schoppet, A.M. Sattler, J.R. Schaefer, and L.C. Hofbauer Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis Atherosclerosis 184 2006 446 447
217. K. Schulze-Osthoff, D. Ferrari, M. Los, S. Wesselborg, and M.E. Peter Apoptosis signaling by death receptors Eur J Biochem 254 1998 439 459
218. I.S. Schuster, M.E. Wikstrom, G. Brizard, J.D. Coudert, M.J. Estcourt, M. Manzur, and et al. TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity Immunity 41 2014 646 656
219. G.R. Screaton, J. Mongkolsapaya, X.N. Xu, A.E. Cowper, A.J. McMichael, and J.I. Bell TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL Curr Biol 7 1997 693 696
220. P. Secchiero, R. Candido, F. Corallini, S. Zacchigna, B. Toffoli, E. Rimondi, and et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice Circulation 114 2006 1522 1530
221. P. Secchiero, A. Gonelli, E. Carnevale, D. Milani, A. Pandolfi, D. Zella, and et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways Circulation 107 2003 2250 2256
222. P. Secchiero, C. Zerbinati, E. Rimondi, F. Corallini, D. Milani, V. Grill, and et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells Cell Mol Life Sci 61 2004 1965 1974
223. L.M. Sedger, M.B. Glaccum, J.C. Schuh, S.T. Kanaly, E. Williamson, N. Kayagaki, and et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice Eur J Immunol 32 2002 2246 2254
224. L.M. Sedger, D.M. Shows, R.A. Blanton, J.J. Peschon, R.G. Goodwin, D. Cosman, and et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression J Immunol 163 1999 920 926
225. N. Seki, U. Toh, T.J. Sayers, T. Fujii, M. Miyagi, Y. Akagi, and et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways Mol Cancer Ther 9 2010 1842 1851
226. A. Shanker, A.D. Brooks, C.A. Tristan, J.W. Wine, P.J. Elliott, H. Yagita, and et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody J Natl Cancer Inst 100 2008 649 662
227. S. Sharma, E.G. de Vries, J.R. Infante, C.N. Oldenhuis, J.A. Gietema, L. Yang, and et al. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors Invest New Drugs 32 2014 135 144
228. J.P. Sheridan, S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, and et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 277 1997 818 821
229. B. Shrestha, A.K. Pinto, S. Green, I. Bosch, and M.S. Diamond CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons J Virol 86 2012 8937 8948
230. B.I. Sikic, H.A. Wakelee, M. von Mehren, N. Lewis, A.H. Calvert, E.R. Plummer, and et al. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI J Clin Oncol 18S 2007 (abstract 14006)
231. A.K. Simon, O. Williams, J. Mongkolsapaya, B. Jin, X.N. Xu, H. Walczak, and et al. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes Proc Natl Acad Sci U S A 98 2001 5158 5163
232. M.P. Simons, K.G. Leidal, W.M. Nauseef, and T.S. Griffith TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules J Leukoc Biol 83 2008 621 629
233. M.P. Simons, J.M. Moore, T.J. Kemp, and T.S. Griffith Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils Infect Immun 75 2007 1265 1271
234. M.R. Smith, F. Jin, and I. Joshi Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2 Clin Cancer Res 13 2007 5528s 5534s
235. M.J. Smyth, E. Cretney, K. Takeda, R.H. Wiltrout, L.M. Sedger, N. Kayagaki, and et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis J Exp Med 193 2001 661 670
236. J. So, A. Pasculescu, A.Y. Dai, K. Williton, A. James, V. Nguyen, and et al. Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy Sci Signal 8 rs3 2015
237. K. Song, Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, and et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression J Exp Med 191 2000 1095 1104
238. J.C. Soria, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, and et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced nonsmall-cell lung cancer J Clin Oncol 29 2011 4442 4451
239. J.C. Soria, E. Smit, D. Khayat, B. Besse, X. Yang, C.P. Hsu, and et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer J Clin Oncol 28 2010 1527 1533
240. D.C. Spierings, E.G. de Vries, E. Vellenga, F.A. van den Heuvel, J.J. Koornstra, J. Wesseling, and et al. Tissue distribution of the death ligand TRAIL and its receptors J Histochem Cytochem 52 2004 821 831
241. M.R. Starkey, D.H. Nguyen, A.T. Essilfie, R.Y. Kim, L.M. Hatchwell, A.M. Collison, and et al. Tumor necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic lung disease Mucosal Immunol 7 2014 478 488
242. K.A. Stegmann, N.K. Bjorkstrom, H. Veber, S. Ciesek, P. Riese, J. Wiegand, and et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection Gastroenterology 138 2010 1885 1897
243. R.M. Steinman, S. Turley, I. Mellman, and K. Inaba The induction of tolerance by dendritic cells that have captured apoptotic cells J Exp Med 191 2000 411 416
244. K. Steinwede, S. Henken, J. Bohling, R. Maus, B. Ueberberg, C. Brumshagen, and et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice J Exp Med 209 2012 1937 1952
245. P.M. Stuart, T.S. Griffith, N. Usui, J. Pepose, X. Yu, and T.A. Ferguson CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival J Clin Invest 99 1997 396 402
246. L. Su, B. Quade, H. Wang, L. Sun, X. Wang, and J. Rizo A plug release mechanism for membrane permeation by MLKL Structure 22 2014 1489 1500
247. T. Suda, T. Takahashi, P. Golstein, and S. Nagata Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 75 1993 1169 1178
248. J.B. Swann, Y. Hayakawa, N. Zerafa, K.C. Sheehan, B. Scott, R.D. Schreiber, and et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function J Immunol 178 2007 7540 7549
249. K. Takeda, K. Okumura, and M.J. Smyth Combination antibody-based cancer immunotherapy Cancer Sci 98 2007 1297 1302
250. K. Takeda, M.J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita, and et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth Cell Immunol 214 2001 194 200
251. K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J.E. Tanner, and et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy J Exp Med 199 2004 437 448
252. C. Tecchio, V. Huber, P. Scapini, F. Calzetti, D. Margotto, G. Todeschini, and et al. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells Blood 103 2004 3837 3844
253. W.D. Thomas, and P. Hersey TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells J Immunol 161 1998 2195 2200
254. M. Thome, P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, and et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors Nature 386 1997 517 521
255. M. Todaro, Y. Lombardo, M.G. Francipane, M.P. Alea, P. Cammareri, F. Iovino, and et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4 Cell Death Differ 15 2008 762 772
256. A.W. Tolcher, M. Mita, N.J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, and et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 J Clin Oncol 25 2007 1390 1395
257. A.E. Tollefson, K. Toth, K. Doronin, M. Kuppuswamy, O.A. Doronina, D.L. Lichtenstein, and et al. Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins J Virol 75 2001 8875 8887
258. B.C. Trauth, C. Klas, A.M. Peters, S. Matzku, P. Moller, W. Falk, and et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis Science 245 1989 301 305
259. T. Trarbach, M. Moehler, V. Heinemann, C.H. Kohne, M. Przyborek, C. Schulz, and et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer Br J Cancer 102 2010 506 512
260. R. Trivedi, and D.P. Mishra Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells Front Oncol 5 2015 69
261. V. Tur, A.M. van der Sloot, C.R. Reis, E. Szegezdi, R.H. Cool, A. Samali, and et al. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design J Biol Chem 283 2008 20560 20568
262. M.H. Tuthill, A. Montinaro, J. Zinngrebe, K. Prieske, P. Draber, S. Prieske, and et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells Oncogene 34 16 2014 2138 2144
263. J.D. Twomey, S.R. Kim, L. Zhao, W.P. Bozza, and B. Zhang Spatial dynamics of TRAIL death receptors in cancer cells Drug Resist Updat 19 2015 13 21
264. E. Ullrich, M. Bonmort, G. Mignot, G. Kroemer, and L. Zitvogel Tumor stress, cell death and the ensuing immune response Cell Death Differ 15 2008 21 28
265. T. Uno, K. Takeda, Y. Kojima, H. Yoshizawa, H. Akiba, R.S. Mittler, and et al. Eradication of established tumors in mice by a combination antibody-based therapy Nat Med 12 2006 693 698
266. J. Unsinger, H. Kazama, J.S. McDonough, T.S. Griffith, R.S. Hotchkiss, and T.A. Ferguson Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism J Immunol 184 2010 6766 6772
267. D.J. Van Antwerp, S.J. Martin, T. Kafri, D.R. Green, and I.M. Verma Suppression of TNF-alpha-induced apoptosis by NF-kappaB Science 274 1996 787 789
268. A.M. van der Sloot, V. Tur, E. Szegezdi, M.M. Mullally, R.H. Cool, A. Samali, and et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor Proc Natl Acad Sci U S A 103 2006 8634 8639
269. J. van Grevenynghe, R.A. Cubas, A. Noto, S. DaFonseca, Z. He, Y. Peretz, and et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis J Clin Invest 121 2011 3877 3888
270. I.A. van Roosmalen, W.J. Quax, and F.A. Kruyt Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? Biochem Pharmacol 91 2014 447 456
271. J. von Pawel, J.H. Harvey, D.R. Spigel, M. Dediu, M. Reck, C.L. Cebotaru, and et al. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer Clin Lung Cancer 15 2014 188 196 (e182)
272. T. Vanden Berghe, A. Linkermann, S. Jouan-Lanhouet, H. Walczak, and P. Vandenabeele Regulated necrosis: the expanding network of non-apoptotic cell death pathways Nat Rev Mol Cell Biol 15 2014 135 147
273. R.L. VanOosten, J.K. Earel, and T.S. Griffith Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors Cancer Gene Ther 13 6 2006 628 632
274. R.L. VanOosten, J.K. Earel Jr., and T.S. Griffith Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity Apoptosis 12 2007 561 571
275. R.L. VanOosten, J.M. Moore, B. Karacay, and T.S. Griffith Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression Cancer Biol Ther 4 2005 1104 1112
276. R.L. VanOosten, J.M. Moore, A.T. Ludwig, and T.S. Griffith Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts Mol Ther 11 2005 542 552
277. N. Varela, C. Munoz-Pinedo, C. Ruiz-Ruiz, G. Robledo, M. Pedroso, and A. Lopez-Rivas Interferon-gamma sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism J Biol Chem 276 2001 17779 17787
278. D.L. Vaux, and A. Strasser The molecular biology of apoptosis Proc Natl Acad Sci U S A 93 1996 2239 2244
279. S. Verma, A. Loewendorf, Q. Wang, B. McDonald, A. Redwood, and C.A. Benedict Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense PLoS Pathog 10 2014 e1004268
280. J. Vilcek Fifty years of interferon research: aiming at a moving target Immunity 25 2006 343 348
281. S. Volpato, L. Ferrucci, P. Secchiero, F. Corallini, G. Zuliani, R. Fellin, and et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults Atherosclerosis 215 2011 452 458
282. J. Voortman, T.P. Resende, M.A. Abou El Hassan, G. Giaccone, and F.A. Kruyt TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib Mol Cancer Ther 6 2007 2103 2112
283. Z.A. Wainberg, W.A. Messersmith, P.F. Peddi, A.V. Kapp, A. Ashkenazi, S. Royer-Joo, and et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer Clin Colorectal Cancer 12 2013 248 254
284. K.W. Wagner, E.A. Punnoose, T. Januario, D.A. Lawrence, R.M. Pitti, K. Lancaster, and et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nat Med 13 2007 1070 1077
285. K. Wahl, M. Siegemund, F. Lehner, F. Vondran, A. Nussler, F. Langer, and et al. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib Hepatology 57 2013 625 636
286. H. Wajant, E. Haas, R. Schwenzer, F. Muhlenbeck, S. Kreuz, G. Schubert, and et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD) J Biol Chem 275 2000 24357 24366
287. H. Wajant, K. Pfizenmaier, and P. Scheurich TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy Apoptosis 7 2002 449 459
288. H.A. Wakelee, A. Patnaik, B.I. Sikic, M. Mita, N.L. Fox, R. Miceli, and et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors Ann Oncol 21 2010 376 381
289. H. Walczak, M.A. Degli-Esposti, R.S. Johnson, P.J. Smolak, J.Y. Waugh, N. Boiani, and et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL EMBO J 16 1997 5386 5397
290. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, and et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 1999 157 163
291. K.P. Wandinger, J.D. Lunemann, O. Wengert, J. Bellmann-Strobl, O. Aktas, A. Weber, and et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis Lancet 361 2003 2036 2043
292. S.H. Wang, Z. Cao, J.M. Wolf, M. Van Antwerp, and J.R. Baker Jr. Death ligand tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis Endocrinology 146 2005 4721 4726
293. Q. Wang, Y. Ji, X. Wang, and B.M. Evers Isolation and molecular characterization of the 5'-upstream region of the human TRAIL gene Biochem Biophys Res Commun 276 2000 466 471
294. H. Wang, L. Sun, L. Su, J. Rizo, L. Liu, L.F. Wang, and et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3 Mol Cell 54 2014 133 146
295. K. Watanabe, K. Okamoto, and S. Yonehara Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP Cell Death Differ 12 2005 10 18
296. J.M. Werner, T. Heller, A.M. Gordon, A. Sheets, A.H. Sherker, E. Kessler, and et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection Hepatology 58 2013 1621 1631
297. J.A. Westwood, P.K. Darcy, P.M. Guru, J. Sharkey, H.J. Pegram, S.M. Amos, and et al. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice J Transl Med 8 2010 42
298. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, and et al. Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
299. N.S. Wilson, B. Yang, A. Yang, S. Loeser, S. Marsters, D. Lawrence, and et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells Cancer Cell 19 2011 101 113
300. M.C. Wolkers, S.J. Bensinger, D.R. Green, S.P. Schoenberger, and E.M. Janssen Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death Immunol Lett 139 2011 25 32
301. M.C. Wolkers, C. Gerlach, R. Arens, E.M. Janssen, P. Fitzgerald, T.N. Schumacher, and et al. Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression Blood 119 2012 798 804
302. G.S. Wu, T.F. Burns, E.R. McDonald 3rd, W. Jiang, R. Meng, I.D. Krantz, and et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene Nat Genet 17 1997 141 143
303. X.N. Wu, Z.H. Yang, X.K. Wang, Y. Zhang, H. Wan, Y. Song, and et al. Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis Cell Death Differ 21 2014 1709 1720
304. A.H. Wyllie, J.F. Kerr, and A.R. Currie Cell death: the significance of apoptosis Int Rev Cytol 68 1980 251 306
305. J. Xu, J.Y. Zhou, W.Z. Wei, and G.S. Wu Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells PLoS One 5 2010 e10226
306. L. Yee, H.A. Burris, M. Kozloff, Z.A. Wainberg, M. Pao, S. Skettino, and et al. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results J Clin Oncol 27 2009 (abstract 4129)
307. L. Yee, M. Fanale, K. Dimick, S. Calvert, C. Robins, J. Ing, and et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L?TRAIL in combination with rituximab on patients with low-grade non-Hodgkin lymphoma J Clin Oncol 25 2007 (abstract 8078)
308. S. Yonehara, A. Ishii, and M. Yonehara A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor J Exp Med 169 1989 1747 1756
309. M.J. Yoon, Y.J. Kang, I.Y. Kim, E.H. Kim, J.A. Lee, J.H. Lim, and et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation Carcinogenesis 34 2013 1918 1928
310. T. Yoshida, T. Shiraishi, M. Horinaka, M. Wakada, and T. Sakai Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin Oncol Rep 18 2007 1239 1242
311. A. Younes, J.M. Vose, A.D. Zelenetz, M.R. Smith, H.A. Burris, S.M. Ansell, and et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma Br J Cancer 103 2010 1783 1787
312. R. Yu, S.M. Albarenque, R.H. Cool, W.J. Quax, A. Mohr, and R.M. Zwacka DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer Cancer Biol Ther 15 2014 1658 1666
313. Y. Zai-Xing, L. Yan, W. Hao, Z. Ye, L. Chang, and Z. Ren-Qian Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis J Clin Lab Anal 22 2008 138 145
314. L. Zamai, M. Ahmad, I.M. Bennett, L. Azzoni, E.S. Alnemri, and B. Perussia Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells J Exp Med 88 1998 2375 2380
315. X.D. Zhang, S.K. Gillespie, J.M. Borrow, and P. Hersey The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis Biochem Pharmacol 66 2003 1537 1545
316. L. Zheng, G. Fisher, R.E. Miller, J. Peschon, D.H. Lynch, and M.J. Lenardo Induction of apoptosis in mature T cells by tumour necrosis factor Nature 377 1995 348 351
317. S.J. Zheng, J. Jiang, H. Shen, and Y.H. Chen Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice J Immunol 173 2004 5652 5658
318. H. Zhuang, W. Jiang, X. Zhang, F. Qiu, Z. Gan, W. Cheng, and et al. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions J Mol Med 91 2013 219 235
319. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. Andre, A. Tesniere, and G. Kroemer The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 2008 1991 2001
320. L. Zitvogel, O. Kepp, and G. Kroemer Immune parameters affecting the efficacy of chemotherapeutic regimens Nat Rev Clin Oncol 8 2011 151 160